Generic Name and Formulations:
Lipid content 0.2g/mL (refined soybean oil); emulsion for IV infusion; contains aluminum.
Indications for INTRALIPID:
To provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (≥5 days). To provide a source of essential fatty acids for prevention of essential fatty acid deficiency (EFAD).
Administer by IV infusion via a peripheral or central vein. Initiate rate at 0.5mL/min for the first 15–30mins; if tolerated, may increase to 1mL/min. Do not infuse >500mL on first day; if tolerated, may increase dose the next day; max: 2.5g/kg/day. EFAD: supply 8–10% of caloric input with Intralipid 20%. For complete parenteral nutrition: supplement with amino acids, carbohydrates, electrolytes, multivitamins and trace elements.
Administer by IV infusion via a peripheral or central vein. Premature infants: initially 0.5g/kg/day; may increase based on ability to eliminate fat; max: 3g/kg/day. Older children: initiate rate at max 0.05mL/min for the first 10–15mins; if tolerated, may increase to 0.5mL/kg/hr. Max dose: 3g/kg/day. EFAD: supply 8–10% of caloric input with Intralipid 20%. For complete parenteral nutrition: supplement with amino acids, carbohydrates, electrolytes, multivitamins and trace elements.
Disturbances of normal fat metabolism (eg, pathologic hyperlipemia, lipoid nephrosis, acute pancreatitis if accompanied by hyperlipidemia).
Risk of deaths in preterm and low birth weight infants: see full labeling. Severe liver damage, pulmonary disease, anemia, blood coagulation disorders, or when there is danger of fat embolism. Monitor serum triglycerides, liver function in long-term use (discontinue if impaired), platelet counts in neonates. Pregnancy (Cat.C). Nursing mothers.
Sepsis, vein irritation, dyspnea, cyanosis, allergic reactions, hyperlipemia, hypercoagulability, nausea, vomiting, headache, flushing, increase in temperature, sweating, sleepiness, chest and back pain, dizziness, liver dysfunction, blood dyscrasias; aluminum toxicity (esp. preterm infants, renal impairment).
Emulsion (100mL, 250mL, 500mL)—1
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Bleeding Disorder Treatments: Hemophilia A
- Guideline Recommendations Offer No OS Benefit for Younger Patients With Rectal Cancer
- Bleeding Disorder Treatments: von Willebrand Disease
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|